The Cooper Companies, Inc. (NYSE:COO)'s President and Non-Independent Director, Robert S. Weiss recently stated, "I mentioned, we generated a lot of cash flow, $466 million of cash flow. If you just extrapolate that, that would be $2.3 billion over the next 5 years, enough to pay off the debt we incurred over the last several years. Our priorities for cash remain the same: To continue to invest in our business; to continue to acquire; to occasionally buy back stock; and to pay down debt, all else. We will continue to expand geographically, put a lot of energy into the BRIC countries the last 5 years. We will continue to acquire, and we did about more than 10 acquisitions the last 3 years, half of them in Surgical, half of them in Vision."
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision and CooperSurgical. CooperVision is engaged in the contact lens industry. CooperVisionâs products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys, Biofinity toric & Biofinity XR toric, Biofinity multifocal, Biofinity toric multifocal, clariti 1 day, clariti 1 day toric, clariti 1 day multifocal, MiSight 1 day, Avaira Vitality and Avaira Vitality toric. CooperSurgical is a fertility and womenâs health company dedicated to assisting women, babies and families around the world. CooperSurgical provides a range of products and services with an emphasis on improving fertility solutions, empowering office-based care, and advancing hospital care within womenâs health. CooperSurgicalâs brands include Paragard, ER-Complete, Fetal Pillow, INSORB, PGT-Complete, RUMI II and others.
THE COOPER COMPANIES, INC. 
